Biodegradable fumarate-based drug-delivery systems for ophthalmic applications

Journal of Biomedical Materials Research - Part A

Volumn 88, Issue 4, 2009, Pages 976-989

  Hacker, M C ^a   Haesslein, A ^a   Ueda, H ^a,f   Foster, W J ^b,c   Garcia, C A ^d   Amnion, D M ^e   Borazjani, R N ^e   Kunzler, J F ^e   Salamone, J C ^e   Mikos, A G ^a  

^a Rice University   (United States)

^b University of Houston   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e BAUSCH AND LOMB   (United States)

^f KYOTO UNIVERSITY   (Japan)

Author keywords

Acetazolamide; Biodegradable polymer implant; Dichlorphenamide; Intraocular drug delivery; Poly(propylene fumarate); Timolol maleate

Indexed keywords

ACETAZOLAMIDE; BIODEGRADABLE POLYMER IMPLANT; DICHLORPHENAMIDE; INTRAOCULAR DRUG DELIVERY; POLY(PROPYLENE FUMARATE); TIMOLOL MALEATE;

BIOCOMPATIBILITY; BLOOD VESSEL PROSTHESES; CHROMATOGRAPHIC ANALYSIS; COMPUTERIZED TOMOGRAPHY; DIAGNOSTIC RADIOGRAPHY; DRUG DELIVERY; DRUG PRODUCTS; DYNAMIC POSITIONING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH PRESSURE LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MEDICAL IMAGING; PERCOLATION (SOLID STATE); PROPYLENE; TOMOGRAPHY; WATER CONTENT;

BIODEGRADABLE POLYMERS;

ACETAZOLAMIDE; DICLOFENAMIDE; DRUG CARRIER; POLY(PROPYLENE FUMARATE); POLYMER; POVIDONE; TIMOLOL MALEATE; UNCLASSIFIED DRUG; WATER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; CONTROLLED STUDY; DEGRADATION; DISSOCIATION; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG STRUCTURE; FEMALE; GRAVIMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMPLANTATION; MICRO-COMPUTED TOMOGRAPHY; MOLECULAR WEIGHT; MOULD; NONHUMAN; POLYMERIZATION; RABBIT; SUSTAINED DRUG RELEASE; TOPICAL TREATMENT; WATER CONTENT;

ACETAZOLAMIDE; ANIMALS; ANTIHYPERTENSIVE AGENTS; BIOCOMPATIBLE MATERIALS; CARBONIC ANHYDRASE INHIBITORS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DICHLORPHENAMIDE; DIURETICS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EYE; FUMARATES; IMPLANTS, EXPERIMENTAL; MOLECULAR STRUCTURE; POLYPROPYLENES; RABBITS; TIMOLOL;

EID: 60349090731     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.31942     Document Type: Article

References (29)

1. Cunha-Vaz JG. The blood-retinal barriers system. Basic concepts and clinical evaluation. Exp Eye Res 2004;78:715-721.
2. Peyman GA, Ganiban GJ. Delivery systems for intraocular routes. Adv Drug Deliv Rev 1995;16:107-123.
3. Colthurst MJ, Williams RL, Hiscott PS, Grierson I. Biomaterials used in the posterior segment of the eye. Biomaterials 2000;21:649-665.
4. Yasukawa T, Ogura Y, Tabata Y, Kimura H, Wiedemann P, Honda Y. Drug delivery systems for vitreoretinal diseases. Prog Retin Eye Res 2004;23:253-281.
5. Geroski DH, Edelhauser HF. Transscleral drug delivery for posterior segment disease. Adv Drug Deliv Rev 2001;52:37-48.
6. Haesslein A, Ueda H, Hacker MC, Jo S, Ammon DM, Borazjani RN, Kunzler JF, Salamone JC, Mikos AG. Long-term release of fluocinolone acetonide using biodegradable fumarate-based polymers. J Control Release 2006;114:251-260.
7. Ueda H, Hacker MC, Haesslein A, Jo S, Ammon DM, Borazjani RN, Kunzler JF, Salamone JC, Mikos AG. Injectable in situ forming poly(propylene fumarate)-based ocular drug delivery systems. J Biomed Mater Res A 2007;83:656-666.
8. Kaur IP, Smitha R, Aggarwal D, Kapil M. Acetazolamide: Future perspective in topical glaucoma therapeutics. Int J Pharm 2002;248:1-14.
9. Ashbum FS, Gillespie JE, Kass MA, Becker B. Timolol plus maximum tolerated antiglaucoma therapy: A one-year followup study. Surv Ophthalmol 1979;23:389-394.
10. Lindskog S. Structure and mechanism of carbonic anhydrase. Pharmacol Ther 1997;74:1-20.
11. Bourges JL, Bloquel C, Thomas A, Froussart F, Bochot A, Azan F, Gurny R, BenEzra D, Behar-Cohen F. Intraocular implants for extended drug delivery: Therapeutic applications. Adv Drug Deliv Rev 2006;58:1182-1202.
12. Wang Y, Challa P, Epstein DL, Yuan F. Controlled release of ethacrynic acid from poly(lactide-co-glycolide) films for glaucoma treatment. Biomaterials 2004;25:4279-4285.
13. Maurice DM. Drug delivery to the posterior segment from drops. Surv Ophthalmol 2002;47:S41-S52.
14. Haesslein A, Hacker MC, Mikos AG. Effect of macromer molecular weight on in vitro ophthalmic drug release from photo-crosslinked matrices. Acta Biomater 2008;4:1-10.
15. Shung AK, Timmer MD, Jo S, Engel PS, Mikos AG. Kinetics of poly(propylene fumarate) synthesis by step polymerization of diethyl fumarate and propylene glycol using zinc chloride as a catalyst. J Biomater Sci Polym Ed 2002;13:95-108.
16. Timmer MD, Carter C, Ambrose CG, Mikos AG. Fabrication of poly(propylene fumarate)-based orthopaedic implants by photo-crosslinking through transparent silicone molds. Biomaterials 2003;24:4707-4714.
17. Braumann T. Determination of hydrophobic parameters by reversed-phase liquid chromatography: theory, experimental techniques, and application in studies on quantitative structure-activity relationships. J Chromatogr A 1986;373:191-225.
18. Kaliszan R. Quantitative structure-retention relationships applied to reversed-phase high-performance liquid chromatography. J Chromatogr A 1993;656:417-435.
19. Holland TA, Bodde EWH, Baggett LS, Tabata Y, Mikos AG, Jansen JA. Osteochondral repair in the rabbit model utilizing bilayered, degradable oligo(poly(ethylene glycol) fumarate) hydrogel scaffolds. J Biomed Mater Res A 2005;75:156-167.
20. Jansen JA, Dhert WJA, Van der Waerden JPCM, Von Recum AF. Semi-quantitative and qualitative histologic analysis method for the evaluation of implant biocompatibility. J Invest Surg 1994;7:123-134.
21. Wang F, Lee T, Wang CH. PEG modulated release of etanidazole from implantable PLGA/PDLA discs. Biomaterials 2002;23:3555-3566.
22. Siepmann J, Gopferich A. Mathematical modeling of bioerodible, polymeric drug delivery systems. Adv Drug Deliv Rev 2001;48:229-247.
23. Aggarwal D, Pal D, Mitra AK, Kaur IP. Study of the extent of ocular absorption of acetazolamide from a developed niosomal formulation, by microdialysis sampling of aqueous humor. Int J Pharm 2007;338:21-26.
24. Macknight AD, McLaughlin CW, Peart D, Purves RD, Carre DA, Civan MM. Formation of the aqueous humor. Clin Exp Pharmacol Physiol 2000;27:100-106.
25. Haesslein A, Hacker MC, Ueda H, Ammon DM, Borazjani RN, Kunzler JF, Salamone JC, Mikos AG. Matrix modifications modulate ophthalmic drug delivery from photo-crosslinked poly(propylene fumarate)-based networks. J Biomater Sci Polym Ed 2008. In press.
26. Klimisch H-J, Deckardt K, Gembardt C, Hildebrand B, Kuttler K, Roe FJC. Subchronic inhalation and oral toxicity of N-vinyl-pyrrolidone-2. Studies in rodents. Food Chem Toxicol 1997;35:1061-1074.
27. Povidone. The United States Pharmacopeia (USP 24) and National Formulary (NF 19), United States Pharmacopeia Convention, Rockville, MD, 2000. p 1372-1373.
28. Miyajima M, Koshika A, Okada J, Kusai A, Ikeda M. The effects of drug physico-chemical properties on release from copoly(lactic/glycolic acid) matrix. Int J Pharm 1998;169:255-263.
29. Jansen JA, de Ruijter JE, Janssen PTM, Paquay YGCk Histological evaluation of a biodegradable polyactive (R)/hydroxyapatite membrane. Biomaterials 1995;16:819-827.